한글목차

흉막염 치료 세계 시장은 2030년까지 1억 2,000만 달러에 달할 전망

2023년에 9,660만 달러로 추정되는 흉막염 치료 세계 시장은 2030년에는 1억 2,000만 달러에 이르고, 분석 기간 2023-2030년의 CAGR은 3.1%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 진통제 요법은 CAGR 3.5%로 성장을 지속하고, 분석 기간 종료 시에는 7,030만 달러에 달할 것으로 예측됩니다. 면역글로불린 치료 분야의 성장률은 분석 기간 동안 CAGR 2.7%로 추정됩니다.

미국 시장은 2,630만 달러로 추정, 중국은 CAGR 6.1%로 성장 예측

미국의 흉막염 치료 시장은 2023년 2,630만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 6.1%로 성장해 2030년에는 시장 규모 2,460만 달러에 달할 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.0%와 2.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

세계의 흉막염 치료 시장- 주요 동향과 촉진요인 정리

보른호름병으로도 알려진 흉막염은 콕사키 B 바이러스로 인한 급성 바이러스 감염입니다. 늑골 주위 근육의 염증(흉막염)에 의한 갑작스런 심한 흉통과 복통이 특징입니다. 증상은 종종 발열, 두통, 근육의 압통을 포함하며, 통증은 심호흡, 기침, 행동으로 인해 악화될 수 있습니다. 흉막염은 주로 소아와 젊은 성인이 앓고 있으며 보통 1-2주간 자연적으로 치료됩니다. 그러나 심각한 통증과 불편함을 유발하기 위해 증상을 완화하고 환자의 QOL을 개선하는 효과적인 통증 관리 및 치료 전략이 필요합니다.

흉막염의 치료는 증상이 자기 한정적이고 바이러스성이기 때문에 증상의 완화가 첫 번째 접근법입니다. 이부프로펜과 나프록센과 같은 비 스테로이드 성 항염증제(NSAIDs)는 통증과 염증을 억제하기 위해 일반적으로 처방됩니다. 통증이 강한 경우 건강 관리 담당자가 더 강한 진통제와 근육 이완제를 권장 할 수 있습니다. 휴식과 충분한 수분 공급도 치료에 필수적입니다. 특히 면역계가 저하된 환자에서는 항바이러스제가 고려되는 경우도 있습니다. 또한, 따뜻한 찜질과 호흡법과 같은 지지 요법은 근육의 불편함을 완화하고 호흡 기능을 개선하는 데 도움이 됩니다.

흉막염 치료 시장의 성장은 여러 요인에 의해 초래됩니다. 첫째, 인지도의 향상과 진단 능력의 향상으로 흉막 투석을 보다 빈번하고 정확하게 확인할 수 있어 효과적인 치료에 대한 수요가 높아지고 있습니다. 둘째, 제약 연구의 진보로 보다 강력하고 표적화된 비스테로이드성 항염증제 및 통증 관리 솔루션이 개발되어 환자 결과가 향상되었습니다. 인구 증가와 여행자 증가도 있어, 세계적으로 바이러스 감염증이 증가하고 있는 것도 시장 확대에 기여하고 있습니다. 게다가, 특히 신흥국에서는 헬스케어 인프라가 정비됨으로써, 치료에의 액세스가 퍼지고 있습니다. 맞춤형 의료 및 맞춤형 치료 계획을 목표로 하는 동향은 흉막염에 특화된 치료법의 개발을 뒷받침하고 있습니다. 마지막으로 제약기업과 연구기관의 전략적 제휴로 신규 치료법의 발견이 가속화되고 시장에 진입하는 신규 치료법의 안정적인 파이프라인이 확보되고 있습니다.

조사 대상 기업 예(전 86건)

• Algen Healthcare Ltd.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co., Ltd.
• Estrellas Life Sciences Pvt. Ltd.
• GSK Plc
• Healthy Life Pharma(P) Ltd.
• Horizon Therapeutics plc
• Lifecare Neuro Products Ltd.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Zyla Life Sciences;

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트(UAE)
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Pleurodynia Treatment Market to Reach US$120.0 Million by 2030

The global market for Pleurodynia Treatment estimated at US$96.6 Million in the year 2023, is expected to reach US$120.0 Million by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Painkillers Therapy, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$70.3 Million by the end of the analysis period. Growth in the Immunoglobulin Therapy segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$26.3 Million While China is Forecast to Grow at 6.1% CAGR

The Pleurodynia Treatment market in the U.S. is estimated at US$26.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$24.6 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Pleurodynia Treatment Market - Key Trends and Drivers Summarized

Pleurodynia, also known as Bornholm disease, is an acute viral infection caused by the Coxsackie B virus. It is characterized by sudden, intense chest or abdominal pain due to inflammation of the muscles around the ribs (pleurisy). Symptoms often include fever, headache, and muscle tenderness, with pain that can be exacerbated by deep breathing, coughing, or movement. Pleurodynia primarily affects children and young adults and typically resolves on its own within a week or two. However, the severe pain and discomfort it causes necessitate effective management and treatment strategies to alleviate symptoms and improve patient quality of life.

The primary approach to treating pleurodynia involves symptomatic relief, as the condition is self-limiting and viral in nature. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are commonly prescribed to reduce pain and inflammation. In cases of severe pain, healthcare providers may recommend stronger analgesics or muscle relaxants. Rest and adequate hydration are also essential components of the treatment regimen. In some instances, antiviral medications may be considered, particularly in patients with compromised immune systems. Additionally, supportive therapies, such as warm compresses and breathing exercises, can help ease muscle discomfort and improve respiratory function.

The growth in the pleurodynia treatment market is driven by several factors. Firstly, increased awareness and better diagnostic capabilities have led to more frequent and accurate identification of pleurodynia, boosting demand for effective treatments. Secondly, advancements in pharmaceutical research have resulted in the development of more potent and targeted NSAIDs and pain management solutions, enhancing patient outcomes. The rise in the global incidence of viral infections, partly due to population growth and increased travel, has also contributed to market expansion. Furthermore, improved healthcare infrastructure, particularly in emerging economies, has made access to treatment more widespread. The trend towards personalized medicine and tailored treatment plans has encouraged the development of specialized therapies for pleurodynia. Lastly, strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery of novel treatment options, ensuring a steady pipeline of new therapies entering the market.

Select Competitors (Total 86 Featured) -

• Algen Healthcare Ltd.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Co., Ltd.
• Estrellas Life Sciences Pvt. Ltd.
• GSK Plc
• Healthy Life Pharma (P) Ltd.
• Horizon Therapeutics plc
• Lifecare Neuro Products Ltd.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Zyla Life Sciences;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Pleurodynia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Awareness of Pleurodynia Throws the Spotlight on Treatment Demand
  • Advancements in Diagnostic Technologies Propel Growth in Pleurodynia Treatment Market
  • Rising Incidence of Viral Infections Generates Demand for Effective Treatments
  • Expanding Research in Antiviral Therapies Sustains Growth in Treatment Options
  • Growing Popularity of Non-Invasive Treatment Methods Spurs Market Expansion
  • Pharmaceutical Investments in Novel Drug Development Enhance Market Opportunities
  • Increasing Incidence of Post-Viral Syndromes Expands Addressable Market Opportunity
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pleurodynia Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Painkillers Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Immunoglobulin Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• JAPAN
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• CHINA
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 40: China 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• EUROPE
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 46: Europe 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• FRANCE
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 55: France 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• GERMANY
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 61: Germany 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 67: Italy 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 73: UK 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 79: Spain 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 85: Russia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 104: Australia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Australia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 106: Australia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• INDIA
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 110: India Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 111: India Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 112: India 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 113: India Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 117: South Korea Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 118: South Korea 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of Asia-Pacific Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 129: Latin America Historic Review for Pleurodynia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 130: Latin America 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Argentina Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 139: Argentina 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Brazil Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 145: Brazil 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Mexico Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 151: Mexico 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of Latin America Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 157: Rest of Latin America 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 162: Middle East Historic Review for Pleurodynia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 163: Middle East 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 170: Iran Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Iran Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 172: Iran 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 176: Israel Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Israel Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 178: Israel 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Saudi Arabia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 184: Saudi Arabia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 188: UAE Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 189: UAE Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 190: UAE 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Rest of Middle East Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 196: Rest of Middle East 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
• AFRICA
  • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 200: Africa Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Africa Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 202: Africa 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION